Maximilian Gabler1, Silke Geier2, Lukas Mayerhoff3,4, Wolfgang Rathmann5. 1. Boehringer Ingelheim, Ingelheim am Rhein, Germany. maximilian.gabler@boehringer-ingelheim.com. 2. Boehringer Ingelheim, Ingelheim am Rhein, Germany. 3. Former employee of Elsevier Health Analytics, Berlin, Germany. 4. Praxis für Integrative Medizin, Hamburg, Germany. 5. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
Abstract
BACKGROUND: The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. METHODS: A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system was used. All patients aged ≥18 years with T2D documented between 1 January 2015 and 31 December 2015 and complete retrospective documentation of ≥5 years (continuous enrollment in the German statutory health system) before 2015 were selected based on a validated algorithm. Cardiovascular disease (CVD) events were identified based on ICD-10 and OPS codes according to a previous clinical study (EMPA-REG OUTCOME trial). RESULTS: The prevalence of T2D in Germany in 2015 was 9.9% (n = 324,708). Using a narrow definition of CVD, the 6-year observation period prevalence of CVD was estimated as 46.7% [95% CI: 46.52%;46.86%]. Applying a wider CVD definition, the proportion of T2D patients who showed a history of CVD was 57.1% [95% CI: 56.9%;57.24%]. The prevalence of CVD in patients with T2D ranged from 36.3 to 57.1%, depending on the observation period and definition of CVD. CONCLUSIONS: The results underline the need for a population-based registration of cardiovascular complications in T2D.
BACKGROUND: The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. METHODS: A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system was used. All patients aged ≥18 years with T2D documented between 1 January 2015 and 31 December 2015 and complete retrospective documentation of ≥5 years (continuous enrollment in the German statutory health system) before 2015 were selected based on a validated algorithm. Cardiovascular disease (CVD) events were identified based on ICD-10 and OPS codes according to a previous clinical study (EMPA-REG OUTCOME trial). RESULTS: The prevalence of T2D in Germany in 2015 was 9.9% (n = 324,708). Using a narrow definition of CVD, the 6-year observation period prevalence of CVD was estimated as 46.7% [95% CI: 46.52%;46.86%]. Applying a wider CVD definition, the proportion of T2D patients who showed a history of CVD was 57.1% [95% CI: 56.9%;57.24%]. The prevalence of CVD in patients with T2D ranged from 36.3 to 57.1%, depending on the observation period and definition of CVD. CONCLUSIONS: The results underline the need for a population-based registration of cardiovascular complications in T2D.
Entities:
Keywords:
Cardiovascular disease; Epidemiological study; Prevalence figures; Secondary data analysis; Type 2 diabetes mellitus
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Katharina Kähm; Michael Laxy; Udo Schneider; Wolf H Rogowski; Stefan K Lhachimi; Rolf Holle Journal: Diabetes Care Date: 2018-01-18 Impact factor: 19.112
Authors: Alexander Thompson; Emanuele Di Angelantonio; Pei Gao; Nadeem Sarwar; Sreenivasa Rao Kondapally Seshasai; Stephen Kaptoge; Peter H Whincup; Kenneth J Mukamal; Richard F Gillum; Ingar Holme; Inger Njølstad; Astrid Fletcher; Peter Nilsson; Sarah Lewington; Rory Collins; Vilmundur Gudnason; Simon G Thompson; Naveed Sattar; Elizabeth Selvin; Frank B Hu; John Danesh Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Bernard Zinman; Silvio E Inzucchi; John M Lachin; Christoph Wanner; Roberto Ferrari; David Fitchett; Erich Bluhmki; Stefan Hantel; Joan Kempthorne-Rawson; Jennifer Newman; Odd Erik Johansen; Hans-Juergen Woerle; Uli C Broedl Journal: Cardiovasc Diabetol Date: 2014-06-19 Impact factor: 9.951